메뉴 건너뛰기




Volumn 8, Issue 10, 2007, Pages 1529-1537

Sertraline for the treatment of depression in coronary artery disease and heart failure

Author keywords

Coronary artery disease; Heart failure; Sertraline; SSRIs

Indexed keywords

ACETYLSALICYLIC ACID; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOPIDOGREL; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; INTERLEUKIN 1; LAMOTRIGINE; MIDAZOLAM; NORCLOZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WARFARIN;

EID: 34447550087     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.10.1529     Document Type: Review
Times cited : (13)

References (86)
  • 1
    • 0031822289 scopus 로고    scopus 로고
    • The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment
    • MUSSELMAN DL, EVANS DL, NEMEROFF CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry (1998) 55:580-592.
    • (1998) Arch. Gen. Psychiatry , vol.55 , pp. 580-592
    • MUSSELMAN, D.L.1    EVANS, D.L.2    NEMEROFF, C.B.3
  • 2
    • 0141609605 scopus 로고    scopus 로고
    • Epidemiology of coronary artery disease and depression
    • RUDISCH B, NEMEROFF CB: Epidemiology of coronary artery disease and depression. Biol. Psychiatry (2003) 54:227-240.
    • (2003) Biol. Psychiatry , vol.54 , pp. 227-240
    • RUDISCH, B.1    NEMEROFF, C.B.2
  • 3
    • 0036174871 scopus 로고    scopus 로고
    • Depression and heart disease: Evidence of a link, and its therapeutic implications
    • JIANG W, KRISHNAN RR, O'CONNOR CM: Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs (2002) 16:111-127.
    • (2002) CNS Drugs , vol.16 , pp. 111-127
    • JIANG, W.1    KRISHNAN, R.R.2    O'CONNOR, C.M.3
  • 4
    • 27744535499 scopus 로고    scopus 로고
    • Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure
    • RUMSFELD JS, JONES PG, WHOOLEY MA et al.: Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am. Heart J. (2005) 150(5)-.961-967.
    • (2005) Am. Heart J , vol.150 , Issue.5 , pp. 961-967
    • RUMSFELD, J.S.1    JONES, P.G.2    WHOOLEY, M.A.3
  • 5
    • 0035944828 scopus 로고    scopus 로고
    • Relation between depression after coronary artery bypass surgery and 12-month outcome: A prospective study
    • CONNERNEY I, SHAPIRO PA, McLAUGHLIN JS et al.: Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. Lancet (2001) 358:1766-1771.
    • (2001) Lancet , vol.358 , pp. 1766-1771
    • CONNERNEY, I.1    SHAPIRO, P.A.2    McLAUGHLIN, J.S.3
  • 6
    • 12844278639 scopus 로고    scopus 로고
    • Patients with depressive symptoms have lower health status benefits after coronary artery bypass surgery
    • MALLIK S, KRUMHOLZ HM, LIN ZQ et al.: Patients with depressive symptoms have lower health status benefits after coronary artery bypass surgery. Circulation (2005) 111:271-277.
    • (2005) Circulation , vol.111 , pp. 271-277
    • MALLIK, S.1    KRUMHOLZ, H.M.2    LIN, Z.Q.3
  • 7
    • 2342433991 scopus 로고    scopus 로고
    • Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure
    • JOYNT KE, WHELLAN DJ, O'CONNOR CM: Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J. Card. Fail. (2004) 10(3):258-270.
    • (2004) J. Card. Fail , vol.10 , Issue.3 , pp. 258-270
    • JOYNT, K.E.1    WHELLAN, D.J.2    O'CONNOR, C.M.3
  • 8
    • 0242468515 scopus 로고    scopus 로고
    • Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure
    • RUMSFELD JS, HAVRANEK EP, MASOUDI F et al.: Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J. Am. Coll. Cardiol. (2003) 42:1811-1817.
    • (2003) J. Am. Coll. Cardiol , vol.42 , pp. 1811-1817
    • RUMSFELD, J.S.1    HAVRANEK, E.P.2    MASOUDI, F.3
  • 9
    • 0034968156 scopus 로고    scopus 로고
    • Depressive symptoms and risk of functional decline and death in patients with heart failure
    • VACCARINO V, KASL S, ABRAMSON J, KRUMHOLZ HM: Depressive symptoms and risk of functional decline and death in patients with heart failure. J. Am. Coll. Cardiol. (2001) 38(1):199-205.
    • (2001) J. Am. Coll. Cardiol , vol.38 , Issue.1 , pp. 199-205
    • VACCARINO, V.1    KASL, S.2    ABRAMSON, J.3    KRUMHOLZ, H.M.4
  • 10
    • 13944254392 scopus 로고    scopus 로고
    • Depressive symptoms and mortality in patients with congestive heart failure: A six-year follow-up study
    • MURBERG TE, FURZE G: Depressive symptoms and mortality in patients with congestive heart failure: a six-year follow-up study. Med. Sci. Monit. (2004), 10(12):CR643-CR648.
    • (2004) Med. Sci. Monit , vol.10 , Issue.12
    • MURBERG, T.E.1    FURZE, G.2
  • 11
    • 13944273412 scopus 로고    scopus 로고
    • Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure
    • SULLIVAN MD, LEVY WC, CRANE BA et al.: Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. Am. J. Cardiol. (2004) 94:1577-1580.
    • (2004) Am. J. Cardiol , vol.94 , pp. 1577-1580
    • SULLIVAN, M.D.1    LEVY, W.C.2    CRANE, B.A.3
  • 12
    • 0038690437 scopus 로고    scopus 로고
    • Depressive symptoms and health-related quality of life: The Heart and Soul Study
    • RUO B, RUMSFELD JS, HLATKY MA et al.: Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA (2003) 290:215-221.
    • (2003) JAMA , vol.290 , pp. 215-221
    • RUO, B.1    RUMSFELD, J.S.2    HLATKY, M.A.3
  • 13
    • 17444387493 scopus 로고    scopus 로고
    • Depression and cardiovascular disease: A reciprocal relationship
    • PLANTE GE: Depression and cardiovascular disease: a reciprocal relationship. Metab. Clin. Exp. (2005) 54(Suppl. 1):45-48.
    • (2005) Metab. Clin. Exp , vol.54 , Issue.SUPPL. 1 , pp. 45-48
    • PLANTE, G.E.1
  • 14
    • 23844524856 scopus 로고    scopus 로고
    • Negative impact of depression on outcomes in patients with coronary artery disease: Mechanisms, treatment considerations, and future directions
    • SHIMBO, D, DAVIDSON KW, HAAS DC, FUSTER V, BADIMON JJ: Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. J. Thromb. Haemost. (2005) 3:897-908.
    • (2005) J. Thromb. Haemost , vol.3 , pp. 897-908
    • SHIMBO, D.1    DAVIDSON, K.W.2    HAAS, D.C.3    FUSTER, V.4    BADIMON, J.J.5
  • 15
    • 20344370468 scopus 로고    scopus 로고
    • Depression in chronic heart failure: Novel pathophysiological mechanisms and therapeutic approaches
    • PARISSIS JT, FOUNTOULAKI K, PARASKEVAIDIS I, KREMASTINOS D: Depression in chronic heart failure: novel pathophysiological mechanisms and therapeutic approaches. Expert Opin. Investig. Drugs (2005) 14(5):567-577.
    • (2005) Expert Opin. Investig. Drugs , vol.14 , Issue.5 , pp. 567-577
    • PARISSIS, J.T.1    FOUNTOULAKI, K.2    PARASKEVAIDIS, I.3    KREMASTINOS, D.4
  • 16
    • 0027316235 scopus 로고
    • The safety of tricyclic antidepressants in cardiac patients: Risk-benefit reconsidered
    • GLASSMAN AH, ROOSE SP, BIGGER JT Jr: The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA (1993) 269:2673-2675.
    • (1993) JAMA , vol.269 , pp. 2673-2675
    • GLASSMAN, A.H.1    ROOSE, S.P.2    BIGGER Jr, J.T.3
  • 17
    • 0031053807 scopus 로고    scopus 로고
    • How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?
    • SHELINE YI, FREEDLAND KE, CARNEY RM: How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am. J. Med. (1997) 102:54-59.
    • (1997) Am. J. Med , vol.102 , pp. 54-59
    • SHELINE, Y.I.1    FREEDLAND, K.E.2    CARNEY, R.M.3
  • 18
    • 0027462948 scopus 로고
    • Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
    • SONG F, FREEMANTLE, N, SHELDON TA et al.: Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br. Med. J. (1993) 306:683-687.
    • (1993) Br. Med. J , vol.306 , pp. 683-687
    • SONG, F.1    FREEMANTLE, N.2    SHELDON, T.A.3
  • 19
    • 33646846111 scopus 로고    scopus 로고
    • Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: An overview
    • CARRASCO JL, SANDNER C: Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int. J. Clin. Pract. (2005) 59(12):1428-1434.
    • (2005) Int. J. Clin. Pract , vol.59 , Issue.12 , pp. 1428-1434
    • CARRASCO, J.L.1    SANDNER, C.2
  • 20
    • 13244262832 scopus 로고    scopus 로고
    • Serotonin reuptake inhibitors and cardiovascular disease: A platelet connection
    • MAURER-SPUREJ E: Serotonin reuptake inhibitors and cardiovascular disease: a platelet connection. Cell. Mol. Life Sci. (2005) 6:159-170.
    • (2005) Cell. Mol. Life Sci , vol.6 , pp. 159-170
    • MAURER-SPUREJ, E.1
  • 21
    • 34447556124 scopus 로고    scopus 로고
    • PFIZER, INC, Zoloft™ (Sertraline) Package Insert. Pfizer, Inc, USA 2002
    • PFIZER, INC.: Zoloft™ (Sertraline) Package Insert. Pfizer, Inc., USA (2002).
  • 22
    • 0344110152 scopus 로고    scopus 로고
    • Pharmakocinetics of selective serotonin reuptake inhibitors
    • HIEMKE C, HARTTER S: Pharmakocinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther (2000) 85:11-28.
    • (2000) Pharmacol. Ther , vol.85 , pp. 11-28
    • HIEMKE, C.1    HARTTER, S.2
  • 23
    • 0028099484 scopus 로고
    • Pharmacology of antidepressants - characteristics of the ideal drug
    • RICHELSON E: Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin. Proc. (1994) 69:1069-1081.
    • (1994) Mayo Clin. Proc , vol.69 , pp. 1069-1081
    • RICHELSON, E.1
  • 24
    • 0031456987 scopus 로고    scopus 로고
    • Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
    • OWENS MJ, MORGAN WN, PLOTT SJ, NEMEROFF CB: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. (1997) 283:1305-1322.
    • (1997) J. Pharmacol. Exp. Ther , vol.283 , pp. 1305-1322
    • OWENS, M.J.1    MORGAN, W.N.2    PLOTT, S.J.3    NEMEROFF, C.B.4
  • 25
    • 0027464837 scopus 로고
    • Clinical pharmacokinetics of selective serotonin reuptake inhibitors
    • VAN HARTEN J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. (1993) 24:203-220.
    • (1993) Clin. Pharmacokinet , vol.24 , pp. 203-220
    • VAN HARTEN, J.1
  • 26
  • 27
    • 0031017313 scopus 로고    scopus 로고
    • Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers
    • RONFELD RA, TREMAINE LM, WILNER KD: Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin. Pharmacokinet. (1997) 32(suppl. 1):22-30.
    • (1997) Clin. Pharmacokinet , vol.32 , Issue.SUPPL. 1 , pp. 22-30
    • RONFELD, R.A.1    TREMAINE, L.M.2    WILNER, K.D.3
  • 28
    • 0030949753 scopus 로고    scopus 로고
    • The role of metabolites of antidepressants in the treatment of depression
    • RUDORFER MV, POTTER WZ: The role of metabolites of antidepressants in the treatment of depression. CNS Drugs (1997) 7:273-312.
    • (1997) CNS Drugs , vol.7 , pp. 273-312
    • RUDORFER, M.V.1    POTTER, W.Z.2
  • 29
    • 0032980470 scopus 로고    scopus 로고
    • Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors
    • 443-466
    • DEVANE CL: Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell. Mol. Neurobiol. (1999) 19(4).-443-466.
    • (1999) Cell. Mol. Neurobiol , vol.19 , Issue.4
    • DEVANE, C.L.1
  • 30
    • 0029051020 scopus 로고
    • Sertraline 50 mg daily: The optimal dose in the treatment of depression
    • PRESKORN SH, LANE RM: Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int. J. Clin. Psychopharmacol. (1995) 10:129-141.
    • (1995) Int. J. Clin. Psychopharmacol , vol.10 , pp. 129-141
    • PRESKORN, S.H.1    LANE, R.M.2
  • 31
    • 0028070312 scopus 로고
    • Therapeutic interchange of fluoxetine and sertraline: Experience in the clinical setting
    • STOCK AJ, KOFOED L: Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting. Am. J. Hosp. Pharm. (1994) 51:2279-2281.
    • (1994) Am. J. Hosp. Pharm , vol.51 , pp. 2279-2281
    • STOCK, A.J.1    KOFOED, L.2
  • 32
    • 0030463740 scopus 로고    scopus 로고
    • Pharmacokinetic drug interaction potential of selective serotonin reaptake inhibitors
    • LANE RM: Pharmacokinetic drug interaction potential of selective serotonin reaptake inhibitors. Int. Clin. Pychopharmacol. (1996) 11(Suppl. 5):31-61.
    • (1996) Int. Clin. Pychopharmacol , vol.11 , Issue.SUPPL. 5 , pp. 31-61
    • LANE, R.M.1
  • 33
    • 0036799221 scopus 로고    scopus 로고
    • Review of sertraline in post-traumatic stress disorder
    • SCHWARTZ AC, ROTHBAUM BO: Review of sertraline in post-traumatic stress disorder. Expert Opin. Pharmacother (2002) 3(10):1489-1499.
    • (2002) Expert Opin. Pharmacother , vol.3 , Issue.10 , pp. 1489-1499
    • SCHWARTZ, A.C.1    ROTHBAUM, B.O.2
  • 34
    • 0031974298 scopus 로고    scopus 로고
    • The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline
    • OZDEMIR V, NARANJO CA, HERRMANN N et al.: The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. J. Clin. Psychopharmacol. (1998) 18(1):55-61.
    • (1998) J. Clin. Psychopharmacol , vol.18 , Issue.1 , pp. 55-61
    • OZDEMIR, V.1    NARANJO, C.A.2    HERRMANN, N.3
  • 35
    • 0030936227 scopus 로고    scopus 로고
    • CYP2D6 inhibition in patients treated with sertraline
    • SPROULE BA, OTTON SV, CHEUNG SW et al.: CYP2D6 inhibition in patients treated with sertraline. J. Clin. Psychopharmacol. (1997) 17(2):102-106.
    • (1997) J. Clin. Psychopharmacol , vol.17 , Issue.2 , pp. 102-106
    • SPROULE, B.A.1    OTTON, S.V.2    CHEUNG, S.W.3
  • 36
    • 0030791275 scopus 로고    scopus 로고
    • Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers
    • ALDERMAN J, PRESKORN SH, GREENBLATT DJ et al.: Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J. Clin. Psychopharmacol. (1997) 17(4):284-291.
    • (1997) J. Clin. Psychopharmacol , vol.17 , Issue.4 , pp. 284-291
    • ALDERMAN, J.1    PRESKORN, S.H.2    GREENBLATT, D.J.3
  • 37
    • 0030770609 scopus 로고    scopus 로고
    • The effect of sertraline on the pharmacokinetics of desipramine and imipramine
    • KURTZ DL, BERGSTROM RF, GOLDBERG MJ, CERIMELE BJ: The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin. Pharmacol. Ther. (1997) 62(2):145-156.
    • (1997) Clin. Pharmacol. Ther , vol.62 , Issue.2 , pp. 145-156
    • KURTZ, D.L.1    BERGSTROM, R.F.2    GOLDBERG, M.J.3    CERIMELE, B.J.4
  • 38
    • 0000375514 scopus 로고
    • Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo
    • P
    • ZUSSMAN BD, DAVIS CC, FOWLES SE et al.: Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br. J. Clin. Pharmacol. (1995) 39:550P-551P.
    • (1995) Br. J. Clin. Pharmacol , vol.39
    • ZUSSMAN, B.D.1    DAVIS, C.C.2    FOWLES, S.E.3
  • 39
    • 0030656608 scopus 로고    scopus 로고
    • Effect of sertraline on plasma nortriptyline levels in depressed elderly
    • SOLAI LK, MULSANT BH, POLLOCK BG et al.: Effect of sertraline on plasma nortriptyline levels in depressed elderly. J. Clin. Psychiatry (1997) 58(10):440-443.
    • (1997) J. Clin. Psychiatry , vol.58 , Issue.10 , pp. 440-443
    • SOLAI, L.K.1    MULSANT, B.H.2    POLLOCK, B.G.3
  • 40
    • 0028348762 scopus 로고
    • Pharmacokinetics of desipramine coadministered with scrtraline or fluoxetine
    • PRESKORN SH, ALDERMAN J, CHUNG M et al.: Pharmacokinetics of desipramine coadministered with scrtraline or fluoxetine. J. Clin. Psychopharmacol. (1994) 14(2):90-98.
    • (1994) J. Clin. Psychopharmacol , vol.14 , Issue.2 , pp. 90-98
    • PRESKORN, S.H.1    ALDERMAN, J.2    CHUNG, M.3
  • 41
    • 0034864627 scopus 로고    scopus 로고
    • Review of sertraline and its clinical applications in psychiatric disorders
    • MCRAE AL, BRADY KT. Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin. Pharmacother. (2001) 2(5):883-892.
    • (2001) Expert Opin. Pharmacother , vol.2 , Issue.5 , pp. 883-892
    • MCRAE, A.L.1    BRADY, K.T.2
  • 42
    • 0029918465 scopus 로고    scopus 로고
    • Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine
    • RAPEPORT WG, WILLIAMS SA, MUIRHEAD DC et al.: Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J. Clin. Psychiatry (1996) 57(Suppl. 1):20-23.
    • (1996) J. Clin. Psychiatry , vol.57 , Issue.SUPPL. 1 , pp. 20-23
    • RAPEPORT, W.G.1    WILLIAMS, S.A.2    MUIRHEAD, D.C.3
  • 43
    • 0030938244 scopus 로고    scopus 로고
    • Interaction of sertraline with clozapine
    • PINNINTI NR, DE LEON J: Interaction of sertraline with clozapine. J. Clin. Psychopharmacol. (1997) 17(2):119-120.
    • (1997) J. Clin. Psychopharmacol , vol.17 , Issue.2 , pp. 119-120
    • PINNINTI, N.R.1    DE LEON, J.2
  • 44
    • 0029953653 scopus 로고    scopus 로고
    • Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors
    • CENTORRINO F, BALDESSARINI RJ, FRANKENBURG FR et al.: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry (1996) 153(6):820-822.
    • (1996) Am. J. Psychiatry , vol.153 , Issue.6 , pp. 820-822
    • CENTORRINO, F.1    BALDESSARINI, R.J.2    FRANKENBURG, F.R.3
  • 45
    • 0034918993 scopus 로고    scopus 로고
    • Sudden cardiac death with clozapine and sertraline combination
    • HOEHNS JD, FOUTS MM, KELLY MW, TU KB: Sudden cardiac death with clozapine and sertraline combination. Ann. Pharmacother. (2001) 35(7-8):862-866.
    • (2001) Ann. Pharmacother , vol.35 , Issue.7-8 , pp. 862-866
    • HOEHNS, J.D.1    FOUTS, M.M.2    KELLY, M.W.3    TU, K.B.4
  • 46
    • 0031732560 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology
    • GOODNICK PJ, GOLDSTEIN BJ: Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. J. Psychopharmacol. (1998) 12(3):S5-S20.
    • (1998) J. Psychopharmacol , vol.12 , Issue.3
    • GOODNICK, P.J.1    GOLDSTEIN, B.J.2
  • 47
    • 0031970013 scopus 로고    scopus 로고
    • Lamotrigine toxicity secondary to sertraline
    • KAUFMAN KR, GERNER R: Lamotrigine toxicity secondary to sertraline. Seizure (1998) 7(2):163-165.
    • (1998) Seizure , vol.7 , Issue.2 , pp. 163-165
    • KAUFMAN, K.R.1    GERNER, R.2
  • 48
    • 0036231396 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitor discontinuation syndrome: A review
    • TAMAM L, OZPOYRAZ N: Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv. Ther. (2002) 19(1):17-26.
    • (2002) Adv. Ther , vol.19 , Issue.1 , pp. 17-26
    • TAMAM, L.1    OZPOYRAZ, N.2
  • 49
    • 0000909213 scopus 로고    scopus 로고
    • A comparison of symptoms following treatment interruption: Evidence from a randomized double-blind trial with fluoxctine, sertraline, and paroxetine
    • FAVA M, ROSENBAUM JF, HOOG S et al.: A comparison of symptoms following treatment interruption: evidence from a randomized double-blind trial with fluoxctine, sertraline, and paroxetine. Biol. Psychiatry (1998) 43(Suppl. 8):69S.
    • (1998) Biol. Psychiatry , vol.43 , Issue.SUPPL. 8
    • FAVA, M.1    ROSENBAUM, J.F.2    HOOG, S.3
  • 50
    • 0034167383 scopus 로고    scopus 로고
    • Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo controlled trial
    • MICHELSON D, FAVA M, AMSTERDAM J et al.: Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo controlled trial. Br. J. Psychiatry (2000) 176:363-368.
    • (2000) Br. J. Psychiatry , vol.176 , pp. 363-368
    • MICHELSON, D.1    FAVA, M.2    AMSTERDAM, J.3
  • 51
    • 0031459202 scopus 로고    scopus 로고
    • Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system
    • STAHL MM, LINDQUIST M, PETTERSSON M et al.: Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur. J. Clin. Pharmacol. (1997) 53(3-4):163-169.
    • (1997) Eur. J. Clin. Pharmacol , vol.53 , Issue.3-4 , pp. 163-169
    • STAHL, M.M.1    LINDQUIST, M.2    PETTERSSON, M.3
  • 52
    • 0030576936 scopus 로고    scopus 로고
    • Blood coagulation and platelet aggegation in major depression
    • MAES M, VAN DER PLANKEN M, VAN GASTEL A et al.: Blood coagulation and platelet aggegation in major depression. J. Affect. Disord. (1996) 40:35-40.
    • (1996) J. Affect. Disord , vol.40 , pp. 35-40
    • MAES, M.1    VAN DER PLANKEN, M.2    VAN GASTEL, A.3
  • 53
    • 0033520025 scopus 로고    scopus 로고
    • Serotonin is associated with coronary artery disease and cardiac events
    • VIKENES K, FARSTAD M, NORDREHAUG JE: Serotonin is associated with coronary artery disease and cardiac events. Circulation (1999) 100:483-489.
    • (1999) Circulation , vol.100 , pp. 483-489
    • VIKENES, K.1    FARSTAD, M.2    NORDREHAUG, J.E.3
  • 54
    • 0036467938 scopus 로고    scopus 로고
    • Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes
    • SHIMBO D, CHILD J, DAVIDSON K et al.: Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am. J. Cardiol. (2002) 89:331-333.
    • (2002) Am. J. Cardiol , vol.89 , pp. 331-333
    • SHIMBO, D.1    CHILD, J.2    DAVIDSON, K.3
  • 55
    • 0028890964 scopus 로고
    • Serotonin uptake inhibitors modulate intracellular calcium mobilization in platelets
    • HELMESTE D, TANG S, REIST C et al.: Serotonin uptake inhibitors modulate intracellular calcium mobilization in platelets. Eur. J. Pharmacol. (1995) 288:373-377.
    • (1995) Eur. J. Pharmacol , vol.288 , pp. 373-377
    • HELMESTE, D.1    TANG, S.2    REIST, C.3
  • 56
    • 0026760806 scopus 로고
    • Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: Relationship to clinical improvement
    • CELADA P, DOLERA M, ALVAREZ E et al.: Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J. Affect. Disord. (1992) 25:243-249.
    • (1992) J. Affect. Disord , vol.25 , pp. 243-249
    • CELADA, P.1    DOLERA, M.2    ALVAREZ, E.3
  • 57
    • 0043180436 scopus 로고    scopus 로고
    • Sertraline Antidepressant Heart Attack Randomized Trial Study Group. Platelet/ endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy
    • SEREBRUANY VL, GLASSMAN AH, MALININ AI et al.: Sertraline Antidepressant Heart Attack Randomized Trial Study Group. Platelet/ endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy. Circulation (2003) 108:939-944.
    • (2003) Circulation , vol.108 , pp. 939-944
    • SEREBRUANY, V.L.1    GLASSMAN, A.H.2    MALININ, A.I.3
  • 58
    • 20044370662 scopus 로고    scopus 로고
    • Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression
    • SEREBRUANY VL, SUCKOW RF, COOPER TB et al.: Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am. J. Psychiatry (2005) 162:1165-1170.
    • (2005) Am. J. Psychiatry , vol.162 , pp. 1165-1170
    • SEREBRUANY, V.L.1    SUCKOW, R.F.2    COOPER, T.B.3
  • 59
    • 0343593736 scopus 로고    scopus 로고
    • An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHART trial): Sertraline Anti-Depressant Heart Attack Trial
    • SHAPIRO PA, LESPERANCE F, FRASURE-SMITH N et al.: An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHART trial): Sertraline Anti-Depressant Heart Attack Trial. Am. Heart J. (1999) 137:1100-1106.
    • (1999) Am. Heart J , vol.137 , pp. 1100-1106
    • SHAPIRO, P.A.1    LESPERANCE, F.2    FRASURE-SMITH, N.3
  • 60
    • 0037077490 scopus 로고    scopus 로고
    • Sertraline treatment of major depression in patients with acute MI or unstable angina
    • GLASSMAN AH, O'CONNOR CM, CALIFF RM et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 288:701-709.
    • (2002) JAMA , vol.288 , pp. 701-709
    • GLASSMAN, A.H.1    O'CONNOR, C.M.2    CALIFF, R.M.3
  • 61
    • 0242488860 scopus 로고    scopus 로고
    • SWENSON JR, O'CONNOR CM, BARTON D et al. AND SERTRALINE ANTIDEPRESSANT HEART ATTACK RANDOMIZED TRIAL (SADHART) GROUP: Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am. J. Cardiol. (2003) 92(11):1271-1276.
    • SWENSON JR, O'CONNOR CM, BARTON D et al. AND SERTRALINE ANTIDEPRESSANT HEART ATTACK RANDOMIZED TRIAL (SADHART) GROUP: Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am. J. Cardiol. (2003) 92(11):1271-1276.
  • 62
    • 0035899867 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitors and myocardial infarction
    • SAUER WH, BERLIN JA, KIMMEL SE: Selective serotonin reuptake inhibitors and myocardial infarction. Circulation (2001) 104(16):1894-1898.
    • (2001) Circulation , vol.104 , Issue.16 , pp. 1894-1898
    • SAUER, W.H.1    BERLIN, J.A.2    KIMMEL, S.E.3
  • 63
    • 0038507402 scopus 로고    scopus 로고
    • Effects of treating depression and low perceived social support on clinical events after myocardial infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial
    • BERKMAN LF, BLUMENTHAL J, BURG M et al.: Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA (2003) 289:3106-3116.
    • (2003) JAMA , vol.289 , pp. 3106-3116
    • BERKMAN, L.F.1    BLUMENTHAL, J.2    BURG, M.3
  • 64
    • 0034806969 scopus 로고    scopus 로고
    • Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction
    • McFARLANE A, KAMATH MV, FALLEN EL et al.: Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am. Heart J. (2001) 142:617-623.
    • (2001) Am. Heart J , vol.142 , pp. 617-623
    • McFARLANE, A.1    KAMATH, M.V.2    FALLEN, E.L.3
  • 65
    • 0041967519 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin
    • SEREBRUANY VL, GLASSMAN AH, MALININ AI et al.: Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur. J. Heart Fail. (2003) 5:517-521.
    • (2003) Eur. J. Heart Fail , vol.5 , pp. 517-521
    • SEREBRUANY, V.L.1    GLASSMAN, A.H.2    MALININ, A.I.3
  • 66
    • 0033621141 scopus 로고    scopus 로고
    • Mechanisms and models in heart failure: A combinatorial approach
    • MANN DL: Mechanisms and models in heart failure: a combinatorial approach. Circulationa (1999) 100:999-1008.
    • (1999) Circulationa , vol.100 , pp. 999-1008
    • MANN, D.L.1
  • 67
    • 0028271405 scopus 로고
    • Basic mechanisms in congestive heat failure: Recognizing the role of pro-inflammatory cytokines
    • MANN DL, YOUNG JB: Basic mechanisms in congestive heat failure: recognizing the role of pro-inflammatory cytokines. Chest (1994) 105:897-904.
    • (1994) Chest , vol.105 , pp. 897-904
    • MANN, D.L.1    YOUNG, J.B.2
  • 68
    • 1642463859 scopus 로고    scopus 로고
    • Inflammatory mediators in chronic heart failure: An overview
    • ANKER SD, VON HAEHLING S: Inflammatory mediators in chronic heart failure: an overview. Heart (2004) 90:464-470.
    • (2004) Heart , vol.90 , pp. 464-470
    • ANKER, S.D.1    VON HAEHLING, S.2
  • 69
    • 0035740739 scopus 로고    scopus 로고
    • A glossary of circulating cytokines in chronic heart failure
    • ADAMOPOULOS S, PARISSIS J, KREMASTINOS D: A glossary of circulating cytokines in chronic heart failure. Eur. J. Heart Fail. (2001) 3:517-526.
    • (2001) Eur. J. Heart Fail , vol.3 , pp. 517-526
    • ADAMOPOULOS, S.1    PARISSIS, J.2    KREMASTINOS, D.3
  • 70
    • 0033282727 scopus 로고    scopus 로고
    • Major depression and activation of the inflammatory response system
    • MAES M: Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. (1999) 461:25-46.
    • (1999) Adv. Exp. Med. Biol , vol.461 , pp. 25-46
    • MAES, M.1
  • 71
    • 0037344950 scopus 로고    scopus 로고
    • Cycokines in depression and heart failure
    • PASIC J, LEVY WC, SULLIVAN MD: Cycokines in depression and heart failure. Psychosom. Med. (2003) 65:181-193.
    • (2003) Psychosom. Med , vol.65 , pp. 181-193
    • PASIC, J.1    LEVY, W.C.2    SULLIVAN, M.D.3
  • 72
    • 0029162558 scopus 로고
    • Cytokine-to-brain communication: A review and analysis of alternative mechanisms
    • WATKINS LR, MAIER SF, GOEHLER LE: Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life Sci. (1995) 57:1011-1026.
    • (1995) Life Sci , vol.57 , pp. 1011-1026
    • WATKINS, L.R.1    MAIER, S.F.2    GOEHLER, L.E.3
  • 73
    • 0035021538 scopus 로고    scopus 로고
    • Cytokine-associated emotional and cognitive disturbances in humans
    • REICHENBERG A, YIRMIYA R, SCHOULD A et al.: Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry (2001) 58:445-452.
    • (2001) Arch. Gen. Psychiatry , vol.58 , pp. 445-452
    • REICHENBERG, A.1    YIRMIYA, R.2    SCHOULD, A.3
  • 74
    • 7944229162 scopus 로고    scopus 로고
    • PARISSISJ, ADAMOPOULOS S, RIGAS A et al.: Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am. J. Cardiol. (2004) 94:1326-1328.
    • PARISSISJ, ADAMOPOULOS S, RIGAS A et al.: Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am. J. Cardiol. (2004) 94:1326-1328.
  • 75
    • 0033057940 scopus 로고    scopus 로고
    • Negative immunoregulatory effects of antidepressants: Inhibition of IFN-γ and stimulation of interleukin-10 secretion
    • MAES M, SONG C, LI A et al.: Negative immunoregulatory effects of antidepressants: inhibition of IFN-γ and stimulation of interleukin-10 secretion. Neuropsychopharmacology (1999) 20:370-379.
    • (1999) Neuropsychopharmacology , vol.20 , pp. 370-379
    • MAES, M.1    SONG, C.2    LI, A.3
  • 76
    • 0034938909 scopus 로고    scopus 로고
    • Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis
    • MOHR D, GOODKIN D, ISLAR J, HAUSER S, GENAIN C: Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch. Neurol. (2001) 58:1081-1086.
    • (2001) Arch. Neurol , vol.58 , pp. 1081-1086
    • MOHR, D.1    GOODKIN, D.2    ISLAR, J.3    HAUSER, S.4    GENAIN, C.5
  • 77
    • 0033945784 scopus 로고    scopus 로고
    • Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease
    • STEIN PK, CARNEY RM, FREEDLAND KE et al.: Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. J. Psychosom. Res. (2000) 48:493-500.
    • (2000) J. Psychosom. Res , vol.48 , pp. 493-500
    • STEIN, P.K.1    CARNEY, R.M.2    FREEDLAND, K.E.3
  • 78
    • 0035940369 scopus 로고    scopus 로고
    • Depression, heart rate variability, and acute myocardial infarction
    • CARNEY RM, BLUMENTHAL JA, STEIN PK et al.: Depression, heart rate variability, and acute myocardial infarction. Circulation (2001) 104:2024-2028
    • (2001) Circulation , vol.104 , pp. 2024-2028
    • CARNEY, R.M.1    BLUMENTHAL, J.A.2    STEIN, P.K.3
  • 79
    • 0942287334 scopus 로고    scopus 로고
    • Increased susceptibility to ventricular arrhythmias in a rodent model of experimental depression
    • GRIPPO AJ, SANTOS CM, JOHNSON RF et al.: Increased susceptibility to ventricular arrhythmias in a rodent model of experimental depression. Am. J. Physiol. Heart Circ. Physiol. (2004) 286:H619-H626.
    • (2004) Am. J. Physiol. Heart Circ. Physiol , vol.286
    • GRIPPO, A.J.1    SANTOS, C.M.2    JOHNSON, R.F.3
  • 80
    • 0032031290 scopus 로고    scopus 로고
    • Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients
    • PEET M, MURPHY B, SHAY J, HORROBIN D: Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol. Psychiatry (1998) 43:315-319.
    • (1998) Biol. Psychiatry , vol.43 , pp. 315-319
    • PEET, M.1    MURPHY, B.2    SHAY, J.3    HORROBIN, D.4
  • 81
    • 0037061915 scopus 로고    scopus 로고
    • Blood levels of long-chain n-3 fatty acids and the risk of sudden death
    • ALBERT CM, CAMPOS H, STAMPFER MJ et al.: Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med. (2002) 346:1113-1118.
    • (2002) N. Engl. J. Med , vol.346 , pp. 1113-1118
    • ALBERT, C.M.1    CAMPOS, H.2    STAMPFER, M.J.3
  • 82
    • 0033015454 scopus 로고    scopus 로고
    • Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation
    • DUNBAR S, KIMBLE L, JENKINS L et al.: Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation. Depress. Anxiety (1999) 9:163-168.
    • (1999) Depress. Anxiety , vol.9 , pp. 163-168
    • DUNBAR, S.1    KIMBLE, L.2    JENKINS, L.3
  • 83
    • 0034597757 scopus 로고    scopus 로고
    • QT dispersion in the surface electrocardiogram in ederly patients with major depression
    • NAHSHONI E, AIZENBERG D, STASBERG B et al.: QT dispersion in the surface electrocardiogram in ederly patients with major depression. J. Affect. Disord. (2000) 60:197-200.
    • (2000) J. Affect. Disord , vol.60 , pp. 197-200
    • NAHSHONI, E.1    AIZENBERG, D.2    STASBERG, B.3
  • 84
    • 0035107201 scopus 로고    scopus 로고
    • Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects
    • SHORES M, PASCUALLY M, LEWIS N, FLATNESS D, VEITH R: Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology (2001) 26:433-439.
    • (2001) Psychoneuroendocrinology , vol.26 , pp. 433-439
    • SHORES, M.1    PASCUALLY, M.2    LEWIS, N.3    FLATNESS, D.4    VEITH, R.5
  • 85
    • 16544392759 scopus 로고    scopus 로고
    • Weight gain during long-term treatment of obsessive - compulsive disorder: A prospective comparison between serotonin reuptake inhibitors
    • MAINA G, ALBERT U, SALVI V, BOGETTO F: Weight gain during long-term treatment of obsessive - compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J. Clin. Psychiatry (2004) 65(10):1365-1371.
    • (2004) J. Clin. Psychiatry , vol.65 , Issue.10 , pp. 1365-1371
    • MAINA, G.1    ALBERT, U.2    SALVI, V.3    BOGETTO, F.4
  • 86
    • 33748324652 scopus 로고    scopus 로고
    • Hyponatremia associated with selective serotonin - reuptake inhibitors in older adults
    • JACOB S, SPINLER SA: Hyponatremia associated with selective serotonin - reuptake inhibitors in older adults. Ann. Pharmacother. (2006) 40(9):1618-1622.
    • (2006) Ann. Pharmacother , vol.40 , Issue.9 , pp. 1618-1622
    • JACOB, S.1    SPINLER, S.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.